Article info
PDFEditorial commentary
MOG antibody disease: the determinants of clinical phenotype and disease activity
- Correspondence to Dr Shahd H M Hamid, Neurology, The Walton Centre NHS Foundation Trust, Liverpool L9 7LJ, UK; shahd.hamid{at}thewaltoncentre.nhs.uk
Citation
MOG antibody disease: the determinants of clinical phenotype and disease activity
Publication history
- Received December 9, 2020
- Revised January 8, 2021
- Accepted January 10, 2021
- First published March 10, 2021.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.